Patients suffering from life-threatening allergies always carry a life-saving companion with them: an adrenaline autoinjector to immediately inject themselves in the event of anaphylactic shock, countering an allergic reaction. Epinephrine is a prescription drug for the treatment of life-threatening allergic emergencies. 

TEVA, a worldwide leader in generic drugs and specialty medicines, offers the adrenaline in single-dose, prefilled disposable autoinjectors. The label developed by Schreiner MediPharm for this injector is provided with abrasion- and scratch-resistant reverse printing. As a result, it is particularly resistant against chemical and mechanical impacts it may encounter while being carried, for example, in a purse or backpack. 

Due to its special material construction and design precisely adapted to the autoinjector’s sophisticated shape, the marking label securely adheres to the device. Thus, the vital product and user information is reliably legible and readily available at all times. An additional cover protecting the label against abrasion or separation is not necessary, which reduces waste and environmental footprint. For product and patient safety, the label features a perforation that clearly and irreversibly indicates any first opening of the cap and thus any potential tampering attempt.  

The TEVA Autoinjector-Label won recognition in the annual North American Tag and Label Manufacturers Institute (TLMI) Competition, which awarded Schreiner MediPharm’s product development with second place in 2019’s “Multi-Process” category. 

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com

For further information, contact:
Schreiner MediPharm, a business unit of
Schreiner Group LP
300 Corporate Drive, Suite 10
Blauvelt, NY 10913
Phone (845) 848-9000
Fax  (845) 848-9041
info@schreiner-medipharm.com 
www.schreiner-medipharm.com